Quidel says it has entered a preliminary letter contract with NIH to support expansion of manufacturing capacity for assays that test for SARS-CoV-2 Antigen.
- Quidel and NIH endeavor to enter into a definitive agreement to support the initiative by mid-September
- Company says NIH RADx-ATP investment would support upgrade and addition of manufacturing lines, expanding capacity for test cassettes from approximately 84 million cassettes per year to in excess of 220 million cassettes per year
To view the source of this information click
To contact the reporter on this story:
To contact the ...